Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
332 stopped studies mapped to Pancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 332 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | Phase 2 | terminated | Jan 4, 2013 | Beth Israel Medical Center | not stated | Not stated |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line… | Phase 2 | terminated | Dec 2, 2011 | University Health Network, Toronto | not stated | Not stated |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally… | Phase 4 | withdrawn | Oct 7, 2015 | Yonsei University | Investigator decided to stop the study because it was difficult to proceed with the study. | Investigator |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | Phase 2 | suspended | Dec 19, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in… | Phase 2 | terminated | May 16, 2013 | Hellenic Cooperative Oncology Group | not stated | Not stated |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | Phase 2 | terminated | Oct 2, 2014 | Allina Health System | lack of funding | Funding |
| NCT02204124 | Whipple Procedure: Standard of Care vs. Thunderbeat | N/A | terminated | Jul 30, 2014 | Washington University School of Medicine | Principal Investigator and Study Sponsor decided to terminate the study early | Investigator |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and… | Phase 2 | terminated | Aug 13, 2013 | Radiation Therapy Oncology Group | Trial would not be completed in a reasonable timeframe per CTEP guidelines | Other (stated, no rule matched) |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | Phase 2 | terminated | Jan 26, 2015 | Case Comprehensive Cancer Center | Competing studies | Other (stated, no rule matched) |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | Phase 2 | terminated | Jan 30, 2009 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or… | Phase 2 | terminated | Feb 27, 2015 | National Health Research Institutes, Taiwan | ROS1 in IHC and gene rearrangement result can not match。No tumor response。 | Other (stated, no rule matched) |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | Phase 2 | terminated | May 24, 2011 | University of Oklahoma | The principal investigator terminated the study due to inactivity and low enrollment | Investigator |
| NCT02105350 | A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer | Phase 1 | withdrawn | Apr 7, 2014 | University Health Network, Toronto | Study was never initiated | Other (stated, no rule matched) |
| NCT02496832 | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With… | N/A | withdrawn | Jul 14, 2015 | University Health Network, Toronto | Study was never initiated | Other (stated, no rule matched) |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant… | Phase 3 | withdrawn | Mar 15, 2017 | University of Louisville | Competing study | Other (stated, no rule matched) |
| NCT01721174 | Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures | N/A | terminated | Nov 5, 2012 | Chinese University of Hong Kong | Poor recruitment | Enrollment / accrual |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With… | Phase 1 / Phase 2 | terminated | Aug 10, 2009 | University of Miami | Lack of Funding | Funding |
| NCT02106871 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC) | Phase 1 | withdrawn | Apr 8, 2014 | The University of Texas Medical Branch, Galveston | Study did not get funded. Study never started | Funding |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | The trial was discontinued early due to no confirmed partial responses. | Other (stated, no rule matched) |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With… | Phase 1 | withdrawn | Aug 5, 2016 | Mayo Clinic | Site dropped study | Other (stated, no rule matched) |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile… | N/A | terminated | Feb 24, 2011 | Weill Medical College of Cornell University | EndoHPB probe is FDA approved and considered standard of care | Other (stated, no rule matched) |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Massachusetts General Hospital | Funding was withdrawn after only 10 participants were enrolled | Enrollment / accrual |
| NCT00604266 | Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar…(PET/MRCP) | — | withdrawn | Jan 30, 2008 | University of Toronto | not stated | Not stated |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct… | Phase 1 | withdrawn | Apr 18, 2017 | City of Hope Medical Center | Company no longer interested in supporting this trial | Sponsor / business decision |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary… | Phase 2 | terminated | Oct 27, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With… | Phase 1 / Phase 2 | terminated | May 22, 2009 | Cornerstone Pharmaceuticals | Suspended trial was not restarted. | Other (stated, no rule matched) |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT01151761 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver… | Phase 2 | terminated | Jun 28, 2010 | Stanford University | Poor accrual | Enrollment / accrual |
| NCT01888965 | Maintenance Dovitinib for Colorectal and Pancreas Cancer | Phase 2 | terminated | Jun 28, 2013 | Georgetown University | Adverse Event issues. | Safety / toxicity |
| NCT00767234 | Permission to Collect Blood Over Time for Research | — | terminated | Oct 7, 2008 | Stanford University | Accrual issues - Low Accrual | Enrollment / accrual |
| NCT01784081 | Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients…(iPC3) | — | withdrawn | Feb 5, 2013 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | study was closed by PI due to no accrual | Enrollment / accrual |
| NCT01911416 | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog… | N/A | withdrawn | Jul 30, 2013 | University of Utah | No accrual | Enrollment / accrual |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Oct 14, 2015 | Roswell Park Cancer Institute | drug supply issues | Drug supply |
| NCT01875549 | Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary… | N/A | withdrawn | Jun 12, 2013 | Kwang Hyuck Lee | no enrollment | Enrollment / accrual |
| NCT00975039 | Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma | Phase 2 | terminated | Sep 11, 2009 | Steba Biotech S.A. | Early end of enrolment with regards to difficulty met to enrol patients . | Enrollment / accrual |
| NCT01814631 | Endoscopic Ultrasound (EUS) Processor Comparison | — | withdrawn | Mar 20, 2013 | AdventHealth | Closed at PI discretion | Other (stated, no rule matched) |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | Early Phase 1 | terminated | Oct 14, 2013 | University of Virginia | From preliminary imaging data, the study was stopped due to futility. | Efficacy / futility |
| NCT00414843 | Storage of Bile From Routine Procedures to Study Risk Factors | — | terminated | Dec 22, 2006 | Indiana University | Decreasing interest in using samples; department infrastructure waned | Other (stated, no rule matched) |
| NCT00843830 | A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed… | Phase 1 | terminated | Feb 13, 2009 | University of Michigan Rogel Cancer Center | Study closed early secondary to inability to obtain grant funding to conduct. | Funding |
| NCT00864513 | Study of Pemetrexed for Second-Line Pancreas Cancer | Phase 2 | terminated | Mar 18, 2009 | Georgetown University | At interim analysis the study did not meet the response criteria to continue | Efficacy / futility |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | Phase 2 | withdrawn | Sep 28, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | Phase 2 | withdrawn | Dec 29, 2011 | Massachusetts General Hospital | The study has been closed due to lack of accrual | Enrollment / accrual |
| NCT00630890 | Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) | Phase 1 | terminated | Mar 7, 2008 | University of California, San Francisco | investigator left UCSF and study was closed prematurely in 2008. No results to report. | Investigator |
| NCT00598091 | A Phase I/Expansion Study of Dasatinib(Gem/Dsat) | Phase 1 | terminated | Jan 18, 2008 | Duke University | Low accrual, unable to meet endpoint in timely manner | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 15, 2019source: clinicaltrials